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Abstract
Objective : This study was conducted to determine a 
difference in the prognosis of stage IIA1 cervical cancer 
compared to stage IIA2 based on the incidence of metastasis 
to pelvic lymph nodes by radical hysterectomy.
Methods : A cross-sectional study was conducted among 108 
stage II cervical cancer patients who had undergone radical 
hysterectomy in the obstetric-gynecologic department of 
Dr. Cipto Mangunkusumo hospital since 2006-2016.
Results : Of 108 patients with cervical cancer stage IIA, 
80 (74%) patients are stage IIA1 and the remaining the 
remaining 28 (26%) patients are stage IIA2. The average 
age of patients at stage IIA2 (47.79 years) younger than 
IIA1 (55.85 years) and also patient at stage IIA1 having a 
higher parity number which is four compared to stage IIA2 
with the number of parity 2. The Involvement of lymph 
node metastasis in patients with stage IIA1 and IIA2 cervical 
cancer were 51 (63.75%) and 16 (57.14%) respectively.
Conclusions : Metastatic factor to lymph node in both 
stages have the same result. There was no difference in the 
proportion of lymph node metastasis occurring in both stage 
IIA cervical cancer stage which was corrected with radical 
hysterectomy and pelvic lymphadenectomy with p = 0.535. 
Changing staging did not seem to improve the prognosis.
Keywords : cervical cancer, lymph node metastatic, stage 
IIA
Abstrak
Tujuan : Membuktikan adanya perbedaan prognosis kanker 
servik stadium IIA1 dibanding stadium IIA2 berdasarkan 
kejadian metastasis ke kelenjar getah bening pelvik yang 
dilakukan histerektomi radikal.
Metode : Dengan menggunakan metode potong lintang 
dilakukan pengambilan data  108 sampel pasien kanker 
serviks stadium IIA yang dilakukan pembedahan histerektomi 
radikal di Departemen Onkologi Ginekologi RSUP. Dr. Cipto 
Mangunkusumo Jakarta sejak tahun 2006 hingga tahun 
2016.
Hasil : Pasien kanker serviks stadium IIA1 sebanyak 80 (74%) 
pasien dan stadium IIA2 sebanyak 28 (26 %) pasien. Pada 
stadium IIA2 (47.79 tahun) didapatkan rata- rata usia pasien 
lebih muda dibandingkan IIA1 (55.85 tahun). Pada stadium 
IIA1 juga didapatkan jumlah paritas yang lebih tinggi yaitu 
4 sedangkan pada stadium IIA2 dengan jumlah paritas 2. 
Keterlibatan metastasis kelenjar getah bening pada pasien 
kanker serviks stadium IIA1 dan IIA2 berjumlah 51 (63.75%) 
dan 16 (57.14%) secara berurutan. Tidak terdapat perbedaan 
proporsi kejadian metastasis kelenjar getah bening pada 
kedua kelompok stadium kanker serviks pada stadium IIA 
dengan nilai p = 0,535.
Kesimpulan : Faktor metastasis kelenjar getah bening pada 
kedua stadium memiliki hasil yang serupa.Tidak terdapat 
perbedaan proporsi kejadian metastasis kelenjar getah 
bening pada kedua kelompok stadium kanker serviks stadium 
IIA1 dan IIA2 yang ditatalaksna dengan histerektomi radikal 
dan limfadenektomi pelvis. Perubahan penetapan stadium 
sepertinya tidak memperbaiki prognosis.
Kata kunci : faktor prognostik , kanker serviks, kelenjar 
getah bening, stage IIA.
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INTRODUCTION
Cervical cancer is the fourth most common 
cancer in the world, but in women, cervical 
cancer was ranked second most after breast 
cancer.1 Nowadays, cervical cancer is one of the 
main problems due to its high incidence and the 
leading cause of death, especially in developing 
country such as Indonesia.2,3 Data from thirteen 
anatomical pathologic centres in Indonesia 
showed that cervical cancer  was ranked fi rst 
among all of gynaecological cancer in women 
(31% from ten most common cancers in women) 
followed by ovarian cancer, endometrial cancer 
and vulvovaginal cancer.2,4
These days, the staging of cervical cancer is 
based on the classifi cation of The International 
Federation of Gynecology and Obstetrics (FIGO) 
which divides cervical cancer into four stages 
based on area and invasion. This classifi cation 
was fi rst used in 1928, until now has been done 
eight times revision, the last revision is in 2009 
at stage 0 and IIA cervical cancer.5 FIGO has 
removed stage 0 because it is still considered as a 
pre-invasive lesion. While stage IIA changes were 
subdivided into two based on tumour size, ie 
IIA1 (Primary lesion size ≤4cm) and IIA2 (Primary 
lesion size >4cm).5 This revision was performed 
after analysis of data, literature and cases found to 
date. This change was considered necessary after 
observing the previously revised IB stage in 1995, 
whereby there is a similar prognosis when stage 
IIA is also subdivided by tumour size.5According 
to Jatupol study,  it was found that the 5-year 
free of disease between stage IB1 and IB2 was 98, 
1% and 82.8% with p value <0.001, another study 
conducted by Teresa also mentioned the number 
of 2 years free of disease between IB1 and IB2 
stages was 92.5% and 74.3% with p value 0.012.6.7 
Both studies showed that the division of stage IB 
into two categories showed different prognosis 
outcomes in stage IB1 had a better prognosis than 
IB 26.7 Recommended treatment of cervical cancer 
patients stage IB to IIA is radical hysterectomy 
(type II-III) and pelvic lymphadenectomy 
(removal of pelvic lymph nodes).8  In general, 
proper treatment and therapy in the early stages 
will have a good prognosis. However, 10-17% of 
early-stage cervical cancers will remain residive 
even if they are recurrent before fi ve years.8 
Successful therapy and prognosis of the patient 
will be largely determined by the presence of 
lymph node involvement in the pelvis. Jatupol 
research suggests that lymph nodes involvement 
reduces the 5-year recurrence rate.7 Other studies 
conducted by Kim also mention the same thing, 
patients with lymph nodes involvement have a 
higher recurrence rate than those who do not.9 
Several factors can be used to predict Lymph 
nodes involvement such as, the size of the primary 
tumour, stage, histology, degree of differentiation 
and lymphovascular invasion.10
It is known that the 5-year survival rate of 
cervical cancer is better in earlier stages. The 
5-year survival rate of women with stage I cervical 
cancer reaches 80-90%, and in stage II reaches 
50-65%. While the 5-year survival rate of women 
with stage III cervical cancer reached 25-35% and 
cervical cancer stage IV less than 15%.8
There is a change in IB stage staging to IB1 
and IB2 stage, as well as stage IIA. There is a 
stage IIA revision to stage IIA1 and stage IIA2. 
It is interesting to observe whether the change 
in staging determination improves the prognosis 
or is there a difference in the prognosis of stage 
IIA1 cervical cancer with stage IIA2 indirectly by 
looking at the metastatic factor of lymph nodes. 
As we know, the dominant prognosis factor in 
early-stage cervical cancer is a metastatic factor 
to the lymph nodes.
METHODS
This research used cross-sectional study design 
at Dr. Cipto Mangunkusumo general hospital, 
Jakarta in 2006 until 2016. The target population 
in this study was cervical cancer patients stage IIA1 
and IIA2. The source population in this study was 
cervical cancer patients stage IIA1 and IIA2 who 
were treated for radical hysterectomy and pelvic 
lymphadenectomy in the Gynecology Oncology 
of RSCM Jakarta since 2006. Meanwhile, we also 
performed exclusions to stage IIA cervical cancer 
patients who received adjuvant chemotherapy 
and were accompanied by another kind of cancer 
disease.
The fi rst step in this research working 
procedure is collecting primary data obtained 
from the Cancer Registration of RSCM Oncology 
Gynecology Division. According to this data, 
then conducted search on RSCM Medical Record 
section and anatomical pathology section, then 
Epidermoid Carcinoma
Adenocarcinoma
Adenosquamous 
Carcinoma
Clear Cell Carcinoma
61 (76.25)
11 (13.75)
8 (10)
0
18 (62.29)
8 (28.57)
2 (7.14)
0
0.928 1.23 0.65 – 2.34
Histopathologic types Stage IIA1n (%)
Stage IIA2
n (%) 95% CIP-value or
Table 2. Characteristics and Comparison of Histopathologic Types between Cervical Cancer Patients Stage IIA1 and IIA2
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adjusted according to inclusion and exclusion 
criteria, so it will get the number patients that can 
be evaluated.
Results Data analysis for lymph node 
involvement is the number, percentage and P 
value. Bivariate analysis was performed to fi nd the 
comparison of KGB proportion at stage IIA1 and 
IIA2 with chi-square analysis If the requirements 
for chi-square are met. If the conditions are not 
met, then the fi sher test will be done. This research 
has received ethical approval from the ethical 
commission of Dr. RSUPN. Cipto Mangunkusumo 
/ Faculty of Medicine University of Indonesia with 
number 962 / UN2.F1 / ETIK / 2016
RESULTS
A total of 108 subjects were recruited in this 
study. Eighty subjects were diagnosed with cervical 
cancer (74%) and patients with stage IIA2 of 28 
cases (26%). Table 1 shows the sociodemographic 
characteristics and comparison of age and parity 
characteristics of both stages. 
Table 1 shows that the mean age of stage IIA2 
patients is younger than IIA1, whereas the mean 
age of patients in stage IIA1 and IIA2 are 55.85 
years and 47.79 years respectively. Comparative 
Age (year)
Mean (SD)
Parity Median 
55.85
(7.98)
4
(0-10)
47.79
(7.38)
2
(0-8)
< 0.0005
<0.0005
0.87
0.55
0.82 – 0.93
0.41 – 0.74
Stage IIa1 Stage IIa2 95% CIP-value 
Table 1. Sociodemographic Characteristics and Comparison of Age and Parity Characteristics of Cervical Cancer Patients 
Stage IIA1 and IIA2
OR
histopathologic outcomes are squamous cell 
carcinoma of 71.6% and 70.2% respectively.3,14
This result also corresponds with other studies 
in France, China and Japan which the results 
showed that the histopathology of squamous cell 
carcinoma was the most common.15-17
hypothesis testing using unpaired T-test showed 
that there were signifi cant differences between 
the two age-based study groups with p <0.0005. 
This is also in accordance with study conducted 
by Jery in Taiwan11, in the study obtained the 
average age of patients in stage IIA1 and IIA2 that 
is 55.1 and 47.7 respectively. Garg also performed 
larger-scale studies with 560 patients, the mean 
age of patients at stage IIA1 (49 years) while at 
stage IIA2 (54 years).12 From these results, we 
can conclude that the mean age of patients with 
stage IIA2 lower in different parts of the world, 
with these lower results it will affect the survival 
rate of each stadium.
Those with IIA1 stagehad a median parity of 4 
(0-10) while those with IIA2stage had a median 
parity of 2 (0-8). The Mann-Whitney test showed 
that there was a signifi cant difference between 
the two stages of study based on parity with p 
<0.0005. Although statistically different, it is 
known that parity did not affect the prognosis of 
cervical cancer. In a study conducted by bjorge 
involving 2870 patients, it was found that parity 
did not affect the prognosis of cervical cancer.13
Histopathological characteristics can be seen in 
table 2. It is known that the most histopathologic 
type is epidermoid carcinoma with the 
number of 79 people (73.15%), the second is 
adenocarcinoma with 19 people (17.59%), and 
the third is adenosquamous carcinoma with ten 
people (9.26 %). This is consistent with previous 
research data conducted by Laila and Anggraeni, 
which obtained the highest percentage of 
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The differences between the two groups can 
be seen by testing the Kolgomorov-Smirnov 
test hypothesis. From this test obtained p-value 
is 0,928 which means there is no relationship 
between histopathology type and stage of 
cervical cancer.
Table 3 illustrates the proportion of lymph 
node metastasis occurring in cervical cancer 
patients Stage IIA1 and IIA2. The result is 51 
(63.75%) of patients with stage IIA1 have lymph 
node metastasis involved, whereas in stage IIA2 
there
 are 16 (57.14%) of patients. An analysis 
was conducted to assess the difference in the 
proportion of lymph node metastasis occurring 
in both cervical cancer stage groups. In this case, 
lymph node metastasis data can be tested with 
Chi-Square test. The results showed no difference 
in the proportion of lymph node metastasis 
occurrence in both cervical cancer stage groups 
between stage IIA1 and IIA2 treated with radical 
hysterectomy and pelvic lymphadenectomy with 
p-value 0.535. Similar results were also obtained 
in the study in Taiwan; this is because the number 
of patients in the study is also small that there are 
only 51 research patients.11
The power of this study was only 53.55%, 
although it did not meet the number of samples, 
but we used using total sampling method to 
increase the power of this study. Therefore, the 
results of the analysis to see the possible difference 
in proportion in this study is not necessarily the 
same as that in the population. So it takes further 
research with more samples to get the result of 
analysis with the exact power.
Considering the results of this study on the 
revision of stage IIA issued by FIGO in 2009 that 
divides stage IIA into stage IIA1 and stage IIA2, 
it turns out that the staging revision does not 
affect the lymph node metastasis rate in both 
stages IIA. As we know lymph node metastasis 
factor is one of the dominant factors that affect 
the prognosis of cervical cancer, thus indirectly 
the prognosis of patients stage IIA1 and IIA2 also 
not much different.
CONCLUSION
There was no difference in the proportion of 
lymph node metastasis occurring in both stage 
IIA1 and IIA2 cervical cancer stage which was 
correlated with radical hysterectomy and pelvic 
lymphadenectomy with p = 0.535. Changes in 
staging did not affect the rate of lymph node 
metastasis in both stage IIA.
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